Dr. Elbuluk discusses the importance of assessing the psychological state of patients by gathering social information such as daily activities, living situation, and work status.1
James Del Rosso, DO, Clinical Editor-in-Chief of JCAD, discusses a new review article published in the August 2024 issue of JCAD, titled “Clindamycin: A Comprehensive
JCAD Clinical Editor-in-Chief, James Del Rosso, DO, shares his thoughts on some of the newly published articles found in the August 2024 issue of The
Dr. Del Rosso discusses the current topical treatments available for patients with atopic dermatitis that have shown consistent efficacy with limited adverse events.
Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster presented findings from the TRuE-V long-term extension (LTE) study, which evaluated changes in serum biomarkers in patients with segmental vitiligo who were randomized in the LTE to apply the vehicle or continue using ruxolitinib 1.5% cream after both groups had used ruxolitinib cream in the parent studies.
Dr. Watchmaker shares statistically significant results from a clinical trial that assessed the ability of a novel serum (Mystro Active Balance Serum; Skinbetter Science) to improve redness, texture, dullness, pore size, and uneven pigmentation in the skin.
Andrew Blauvelt, MD, MBA, a dermatologist at the Oregon Medical Research Center in Portland, Oregon, discusses the impact Ruxolitinib cream has on itch in patients with atopic dermatitis which has been a predominant issue in disease symptoms.
Dr. Friedman reviews one of his sessions from the AAD 2023 Annual Meeting, in which he discussed dysbiosis of the skin and how this contributes to inflammatory skin diseases.
Dr. Draelos discusses the process of defining skin quality and the skin parameters that were chosen for this purpose while conducting research on a novel serum (Mystro Active Balance Serum; Skinbetter Science).
Dr. Strober focuses on difficult-to-treat areas in patients with psoriasis and the tremendous impact on quality of life this disease can have.
In this series, board-certified dermatologists discuss new and emerging treatments for patients with vitiligo.
In this four-video series, experts in the field of medical dermatology discuss current and new treatment options for psoriasis and vitiligo.
James Del Rosso, DO, Clinical Editor-in-Chief of JCAD, discusses a new review article published in the August 2024 issue of JCAD, titled “Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.” Read the full article on jcadonline.com. Reference:
